The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 4 , Pages 977-984, October 2009

Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury

  • Neel R. Sodha, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
  • ,
  • Richard T. Clements, PhD

      Affiliations

    • Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
  • ,
  • Jun Feng, MD, PhD

      Affiliations

    • Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
  • ,
  • Yuhong Liu, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
  • ,
  • Cesario Bianchi, MD, PhD

      Affiliations

    • Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
  • ,
  • Eszter M. Horvath, MD

      Affiliations

    • Department of Surgery, University of Medicine and Dentistry of New Jersey, Newark, NJ
  • ,
  • Csaba Szabo, MD, PhD

      Affiliations

    • Ikaria, Inc, Seattle, Wash
  • ,
  • Gregory L. Stahl, PhD

      Affiliations

    • Center for Experimental Therapeutics & Reperfusion Injury, Brigham & Women's Hospital, Harvard Medical School, Boston, Mass
  • ,
  • Frank W. Sellke, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationAddress for reprints: Frank W. Sellke, MD, 110 Francis St, LMOB 2A, Boston, MA 02215.

Received 15 March 2008; received in revised form 2 July 2008; accepted 7 August 2008. published online 15 June 2009.

Introduction

Hydrogen sulfide is produced endogenously in response to myocardial ischemia and thought to be cardioprotective. The mechanism underlying this protection has yet to be fully elucidated, but it may be related to sulfide's ability to limit inflammation. This study investigates the cardioprotection provided by exogenous hydrogen sulfide and its potential anti-inflammatory mechanism of action.

Methods

The mid left anterior descending coronary artery in 14 Yorkshire swine was acutely occluded for 60 minutes, followed by reperfusion for 120 minutes. Controls (n = 7) received placebo, and treatment animals (n = 7) received sulfide 10 minutes before and throughout reperfusion. Hemodynamic and functional measurements were obtained. Evans blue and triphenyl tetrazolium chloride staining identified the area at risk and infarction. Coronary microvascular reactivity was assessed. Tissue was assayed for myeloperoxidase activity and proinflammatory cytokines.

Results

Pre-ischemia/reperfusion hemodynamics were similar between groups, whereas post-ischemia/reperfusion mean arterial pressure was reduced by 28.7 ± 5.0 mm Hg in controls versus 6.7 ± 6.2 mm Hg in treatment animals (P = .03). Positive first derivative of left ventricular pressure over time was reduced by 1325 ± 455 mm Hg/s in controls versys 416 ± 207 mm Hg/s in treatment animals (P = .002). Segmental shortening in the area at risk was better in treatment animals. Infarct size (percent of area at risk) in controls was 41.0% ± 7.8% versus 21.2% ± 2.5% in the treated group (P = .036). Tissue levels of interleukin 6, interleukin 8, tumor necrosis factor-alpha, and myeloperoxidase activity decreased in the treatment group. Treated animals demonstrated improved microvascular reactivity.

Conclusions

Therapeutic sulfide provides protection in response to ischemia/reperfusion injury, improving myocardial function, reducing infarct size, and improving coronary microvascular reactivity, potentially through its anti-inflammatory properties. Exogenous sulfide may have therapeutic utility in clinical settings in which ischemia/reperfusion injury is encountered.

Abbreviations and Acronyms: H2S, hydrogen sulfide, IL, interleukin, I/R, ischemia/reperfusion, KATP, kidney adenosine triphosphate, LAD, left anterior descending, LV, left ventricular, LV dP/dt, first derivative of left ventricular pressure over time, MPO, myeloperoxidase, TNF-α, tumor necrosis factor-alpha

CTSNet classification: 23, 31

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by National Heart, Lung, and Blood Institute grant HL69024-02. N.R.S. and R.T.C. are supported in part by National Institutes of Health grant T-32HL076130-02 and the Irving Bard Memorial Fellowship. Partial funding for this project was provided by Ikaria, Inc, Seattle, Wash.

PII: S0022-5223(09)00565-0

doi:10.1016/j.jtcvs.2008.08.074

The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 4 , Pages 977-984, October 2009